Altamira Therapeutics Ltd. Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets
Altamira Therapeutics Ltd. (CYTOF) reported Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets of CHF 346.04 thousand for the 12-month period ending 2022-12-31, per its 20-F filed 2023-05-16.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets · last filed 2023-05-16
CHF
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month as first filed |
|---|---|---|
| 2022-12-31 | 346.04K CHF 20-F · filed 2023-05-16 | |
| 2021-12-31 | 1.22M CHF 20-F · filed 2023-05-16 | |
| 2020-12-31 | 351.40K CHF 20-F · filed 2023-05-16 | |
| 2019-12-31 | 226.60K CHF 20-F · filed 2022-04-12 | 228.92K CHF 20-F · filed 2020-04-16 |
| 2018-12-31 | 27.73K CHF 20-F · filed 2021-03-31 | 42.76K CHF 20-F · filed 2019-03-14 |
| 2017-12-31 | 354.85K CHF 20-F · filed 2020-04-16 | |
| 2016-12-31 | 290.78K CHF 20-F · filed 2019-03-14 | |
| 2015-12-31 | 311.67K CHF 20-F · filed 2018-03-22 |
CHE
| Period end | Expense From Equitysettled Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets 12 month |
|---|---|
| 2021-12-31 | 1.22M CHE 20-F · filed 2022-04-12 |